目的 分析湖北省第三人民医院住院患者抗新型冠状病毒肺炎（COVID-19）药物的使用情况。方法 收集2020年1月24日-2020年2月19日湖北省第三人民医院已出院的110例COVID-19确诊患者的临床资料，采用世界卫生组织推荐的限定日剂量（DDD）法对药物总金额、用药频度（DDDs）、限定日费用（DDC）和排序比（B/A）进行统计分析。结果 药物总金额排序居前3位的药物类别分别为免疫增强药、喹诺酮类和碳青霉烯类，排序居前3位的药品依次为人免疫球蛋白、莫西沙星和美罗培南。DDDs排序居前3位的药物类别分别为免疫增强药、糖皮质激素类及质子泵抑制药，排序居前3位的药品依次为人免疫球蛋白、甲泼尼龙和莫西沙星。DDC较高的有药品有美罗培南、莫西沙星和哌拉西林钠/舒巴坦钠；B/A较高的有甲泼尼龙、蒙脱石散、奥司他韦，B/A较低的有美罗培南、头孢哌酮钠舒巴坦钠和头孢哌酮钠/他唑巴坦钠。结论 湖北省第三人民医院COVID-19药物的使用基本合理，但仍然存在不足，需进一步加强管理，其中抗菌药物的同步性较差，临床应用合理性有待考证。

Objective To analyze the utilization of anti-new coronavirus disease 2019 (COVID-19) drugs of inpatients in Hubei No. 3 People's Hospital. Methods The clinical data of 110 COVID-19 patients diagnosed in the Third People's Hospital of Hubei Province from January 24, 2020 to February 19, 2020 were collected and analyzed. Total drug amounts, defined daily dose system (DDDs), defined daily cost (DDC), and sequencing ratio (B/A) were analyzed by defined daily dose (DDD) method recommended by the world health organization (WHO). Results The top three drug categories in terms of total drug amounts were immune enhancers, quinolones, and carbapenems. The drugs with top three total drug amounts were human immunoglobulin, moxifloxacin, and meropenem. The drug categories with top three DDDs were immune enhancers, glucocorticoids, and proton pump inhibitors. The top three drugs ranked by DDDs were human immunoglobulin, methylprednisolone, and moxifloxacin, respectively. DDC of meropenem, moxifloxacin, and piperacillin/sulbactam were higher. Methyl prednisolone, montmorillonite powder, and oseltamivir had higher B/A, and B/A of meropenem, cefoperazone/sulbactam, and cefoperazone/tazobartan were lower. Conclusion The utilization of anti-COVID-19 drugs in the Third People's Hospital of Hubei Province is rational on the whole, but there are still some problems, which needs further efforts to strengthen the management and intervention. The synchrony of antibiotics is poor, and their rationality of clinical application remains to be proved.

R978.1

湖北省卫生健康委员会科研项目（WJ2019F170）；武汉市中青年医学骨干人才项目（武卫生计生[2017]51号）